Astria Therapeutics (ATXS) Prices 10.34M Share Offering at $12.09/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
January 30, 2024 9:08 AM ESTBOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Astria Therapeutics, Astria, the Company, our, or us) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the pricing of an underwritten offering of 10,340,000 shares of its common stock. Each share of common stock is being sold at a price of $12.09. The aggregate gross proceeds... More
